Sodium-dependent vitamin C transporter (SVCT) 2-mediated L-ascorbic acid (AA) uptake is required in osteoblast-like differentiation of MC3T3-E1 cells, and prostaglandin E2 (PGE2) is among the most important local factors in bone formation, but the detailed mechanism by which PGE2 induces osteoblast differentiation remains obscure. We revealed that PGE2 induced AA uptake and osteoblast-like differential markers including alkaline phosphatase, collagen, osteocalcin expression, and mineralization in MC3T3-E1 cells. Inhibition of AA uptake by SVCT2 short isoform functioning as a dominant-negative mutant not only robustly attenuated PGE2-induced markers expression and mineralization, but also decreased their basal levels. However, upregulation of AA uptake resulted from PGE2-induced plasma membrane translocation of cytoplasm SVCT2, and this effect was abolished by pretreatment with EP4 receptor antagonist, AH-23848B or cAMP-dependent protein kinase A (PKA) inhibitor, H-89. Moreover, we showed SVCT2 physically interacted with PKA in immunoprecipitates, and PKA phosphorylated SVCT2 in vitro and in intact cells at Ser402 and Ser639 sites; however, mutation of Ser402 or/and Ser639 in SVCT2 severely diminished SVCT2 translocation in response to PGE2. Together, these results suggest that PGE2-induced SVCT2 plasma membrane translocation through EP4 receptor and subsequent phosphorylation of SVCT2 at Ser402 and Ser639 sites by PKA results in an increase of AA uptake and consequent promotion of osteoblast-like differentiation in MC3T3-E1 cells.
MC3T3-E1 preosteoblast, an osteoblastic cell line derived from normal mouse calvaria expresses osteoblast-like differential markers and forms mineralized extracellular matrix only after exposure to L-ascorbic acid (reduced vitamin C, AA). 1, 2 AA stimulates procollagen hydroxylation, processing, and fibril assembly followed by the dramatic induction of specific genes associated with the osteoblastic phenotype, including alkaline phosphatase (ALP), osteopontin, and osteocalcin (OCN). 3, 4 Sodium-dependent vitamin C transporters 1 and 2 (SVCT1, 2) facilitate the transport of AA, [5] [6] [7] and sodiumdependent AA transport is required for MC3T3-E1 cells to achieve the millimolar intracellular AA concentration that is necessary for maximal prolyl hydroxylase activity and expression of the osteoblast phenotype. 8 We had demonstrated that SVCT2 instead of SVCT1 is expressed in MC3T3-E1 cells, 9 Ca 2 þ , PO 4
3À
, or Zn 2 þ enhances osteoblast-like differentiation through increase of SVCT2 expression and AA uptake, 10, 11 and SVCT2 overexpression in MC3T3-E1 cells stimulates mineralization and promotes differential marker genes expression. 12 Additionally, in SVCT2-deficient mouse, AA level was undetectable or markedly reduced in the blood and tissues, and the SVCT2-deficient mice died within a few minutes of birth due to respiratory failure and intraparenchymal brain hemorrhage, suggesting that SVCT2 is required for transport of AA into many tissues and plays an important role in the development of mouse. 7 Prostaglandins (PGs) are produced both in skeletal tissue and bone cell culture in response to various stimulus, and are among the most important local factors with autocrine/ paracrine roles in bone. 13 Among the various PGs produced in bone tissue, the most abundant one is prostaglandin E2 (PGE2), and it appears to be of utmost importance in bone physiology. Although PGE2 is initially described as a potent bone-resorbing substance, 14, 15 accumulated evidence indicates that PGE2 is a potent stimulator of bone formation in vivo and in vitro. [16] [17] [18] [19] [20] It was reported that PGE2 induced ALP activity and increased collagen protein synthesis in MC3T3-E1 cells, 21, 22 and continuous exposure of fetal rat calvaria cells to PGE2 induced a significant increase in mineralized bone nodule formation. 23, 24 However, the detailed mechanism by which PGE2 induces osteoblast differentiation remains obscure.
In this study, we suggest that PGE2 induces plasma membrane localization of cytoplasm SVCT2 through EP4 receptor and phosphorylation of SVCT2 at Ser402 and Ser639 sites by cAMP-dependent protein kinase A (PKA), followed by an increase of AA transport into cells, which consequently leads to stimulation of osteoblast-like differentiation in MC3T3-E1 cells.
Results
PGE2 induces osteoblast-like differentiation and AA uptake. To assess the effects of PGE2 on osteoblast-like differentiation in MC3T3-E1 cells, we performed long-term cultures and analysis of early-stage differential markers including ALP, collagen, and late-stage non-collagenous bone matrix marker, OCN expression as well as mineralization in MC3T3-E1 cells. Cells treated with vehicle underwent robustly osteoblast-like differentiation exhibiting time-dependent increases in ALP, collagen-specific hydroxyproline (Hyp), OCN levels, and mineralization ( Figure 1 ). However, 1 mM of PGE2 treatment for different times consistently increased ALP activity and Hyp contents by 2-to 3-fold over the vehicle treatment at all time points (Figure 1a and b), and PGE2 from 1 nM to 1 mM dosedependently induced ALP and Hyp levels as well as ALP and a(I)procollagen mRNA expression in confluent cells (Supplementary Figure S1A and B). Moreover, PGE2 treatment for different times robustly stimulated OCN expression and formation of von-Kossa stainable mineralized nodules over vehicle treatment at all time points (Figure 1c and d) .
To determine whether PGE2 induces AA uptake, cells were treated with 1 mM of PGE2 for 1 h, and then subjected to [l- 14 C]AA uptake, the kinetic parameters including K m and V max were applied to assess the effects of PGE2. PGE2 increased the V max values of AA uptake by approximately threefold over the vehicle, whereas it did not obviously change the K m values of AA uptake (Figure 1e and f) . Similarly, longterm cultures of primary calvarial osteoblasts indicated 1 mM of PGE2 treatment for different times also robustly induced AA uptake, and significantly increased osteoblast differential markers including ALP, Hyp, and OCN expression as well as mineralization (Supplementary Figure S3A-F) . Together, PGE2 stimulates osteogenic markers expression as well as mineralization in MC3T3-E1 cells and primary calvarial osteoblasts, and PGE2 induces AA uptake with increases of V max and no change in K m values.
SVCT2 and AA uptake are required in PGE2-induced osteoblast-like differentiation. Human SVCT2 short isoform (dnSVCT2) functions as a dominant-negative inhibitor in AA uptake, 25 we attempted to clone the mouse dnSVCT2 cDNA and generated dnSVCT2-expressing retrovirus to examine whether SVCT2 and AA uptake mediate PGE2-induced osteoblast-like differentiation in MC3T3-E1 cells. Overexpression of dnSVCT2 in cells infected with dnSVCT2-expressing retrovirus was verified by Western blotting, and the effect of dnSVCT2 on AA uptake was assessed by kinetic parameters. Expression of dnSVCT2 led to approximately 8-fold increases of dnSVCT2 without change of endogenous SVCT2 levels in whole cell lysates ( Figure 2a) ; however, no obvious difference in K m values of AA uptake was observed between cells expressing either control EGFP or dnSVCT2, whereas dnSVCT2 did decrease the V max values to approximately 39% of control EGFP (Figure 2b and c) .
PGE2 stimulating AA uptake as well as osteoblast-like differentiation in MC3T3-E1 cells prompted us to hypothesize that SVCT2-mediated AA uptake is required in PGE2-induced osteoblast-like differentiation. Similarly, we performed longterm cultures and analysis of ALP, collagen, and OCN expression as well as mineralization in MC3T3-E1 cells infected with either control EGFP-or dnSVCT2-expressing viruses, followed by stimulation with PGE2 for different times. Infection with either EGFP or dnSVCT2 expression retrovirus did not markedly affect the cell proliferation and cell morphology, and PGE2 treatment for different times in EGFP-expressing cells significantly stimulated ALP, collagen, and OCN expression as well as mineralization at all time points, whereas overexpression of dnSVCT2 not only Figure 1 PGE2 induces osteoblast-like differentiation and [l- 14 C]AA uptake in MC3T3-E1 cells. Twenty four hours after plated, cells were precultured in serumfree aMEM containing 1 mg/ml of indomethacin for 3 h, and further treated along with 1 mM of PGE2 ( þ ) or vehicle (À) for indicated times (a-d) or 1 h (e, and f). Then, cells were harvested for ALP activity (a) and Hyp contents (b) assays, Western blotting assays for OCN expression (c), von Kosa staining, (d) and AA uptake assays by using different concentrations of [l- 14 C]AA (e, and f). Numerical data were expressed as mean7S.D. from at least three independent cultures, *Po0.05; **Po0.01 versus vehicle-treated cells. Kinetic constants of AA uptake, K m and V max , were calculated by fitting the data to a double reciprocal plot, and expressed as mM, and pmol/10 6 cells/min respectively significantly inhibited PGE2-induced osteogenic markers expression and mineralization, but also decreased their basal levels at all time points (Figure 2d-g ). Together, dnSVCT2 functioning as a dominant inhibitor for AA uptake in MC3T3-E1 cells not only robustly inhibited PGE2-induced osteoblastlike differential markers expression and mineralization, but also significantly decreased their basal levels.
Membrane localization of SVCT2 results in PGE2-induced AA uptake. To determine the mechanism by which PGE2 induces AA uptake, SVCT2 expression levels in whole cells and subcellular fractions in response to PGE2 were examined. Although 1 mM of PGE2 treatment for 1 h robustly increased AA uptake (Figure 1e and f), both Northern blotting and Western blotting assays suggested that PGE2 treatment within 1 h did not obviously induce SVCT2 mRNA and protein expression (Figure 3a and b).
Subcellular distribution of SVCT2 was further examined by Western blotting, and results revealed that PGE2 robustly increased plasma membrane SVCT2 levels, and concurrently decreased cytoplasm SVCT2 levels in timeand dose-dependent manners (Figure 3c and e), consistent with the results from uptake assays indicating that PGE2 time-and dose-dependently stimulated AA uptake in MC3T3-E1 cells (Figure 3d and f). Moreover, immunostaining for endogenous SVCT2 protein further indicated that in unstimulated cells, SVCT2 was mainly distributed diffusely in the cytoplasm (Figure 4g ), however, 1 h after PGE2 stimulation, SVCT2 molecule was largely translocated to the plasma membrane in a punctuate pattern (Figure 4h ). Figure 2 SVCT2 and AA uptake mediate PGE2-induced osteoblast-like differentiation in MC3T3-E1 cells. MC3T3-E1 cells were infected with dnSVCT2 or EGFP expression retrovirus for 24 h, then, cells were either harvested for Western blotting assay for dnSVCT2 expression (a), uptake assay by using different concentrations of [l- 14 C]AA (b, and c) or precultured in serum-free aMEM containing 1 mg/ml of indomethacin for 3 h, and further treated along with PGE2 ( þ ) or vehicle (À) for indicated times. After PGE2 treatment, cells were harvested for ALP activity (d) and Hyp contents (e) assays, Western blotting for OCN expression (f), von Kosa staining (g). Numerical data were expressed as mean7S.D. from at least three independent cultures, *Po0.05; **Po0.01 versus vehicle-treated and EGFP virus-infected cells. Kinetic constants of AA uptake, K m and V max , were calculated by fitting the data to a double reciprocal plot, and expressed as mM and pmol/10 6 cells/min, respectively result, PGE2 time-dependently increased AA uptake in primary calvarial osteoblasts too (Supplementary Figure  S3G and H). Together, SVCT2 plasma membrane localization instead of upregulation of SVCT2 mRNA and protein expression in response to PGE2 results in stimulation of AA uptake.
EP4 receptor and PKA activation are required in SVCT2 translocation. PGE2 acts through at least four subtypes of rhodopsin-type G protein-coupled receptors, named EPs: EP1 raises intracellular Ca 2 þ concentration, EP2, and EP4 simulate adenylate cyclase (AC), and EP3 decreases intracellular cAMP concentration.
26 EP2 and EP3 mRNA expression was not detectable in MC3T3-E1 cells even with 15 mg poly(A) þ RNA in Northern blotting, only EP1 and EP4 are expressed in MC3T3-E1 cells. 27 To determine which EP receptor subtypes were involved in PGE2-induced SVCT2 translocation and osteoblast-like differentiation, selective EP1 or EP4 receptor antagonist, either AH-6809 or AH-23848B was applied for pretreatment in MC3T3-E1 cells, followed by stimulation with 1 mM of PGE2. AH-23848B instead of AH-6809 dose-dependently inhibited SVCT2 plasma membrane localization and concurrently increased the accumulation of SVCT2 in cytoplasm of PGE2-treated cells, and 10 mM of AH-23848B almost completely abrogated PGE2-induced plasma membrane localization of SVCT2 (Figure 4a and b). Consistent with these results, AH-23848B but not AH-6809 dose-dependently inhibited AA uptake in response to PGE2, and 10 mM of AH-23848B almost completely diminished PGE2-induced AA uptake (Figure 4d and e). Similarly, immunostaining results revealed that within 1 h, SVCT2 molecule was largely translocated to the plasma membrane in a punctuate pattern in response to PGE2 (Figure 4g Activation of EP4 receptor simulates AC, and subsequently increases intracellular cAMP concentration, which further leads to increases of PKA activity. 26 To test whether this signaling cascade is involved in PGE2-induced SVCT2 plasma membrane localization and AA uptake, we examined the cAMP levels and PKA activity in MC3T3-E1 cells treated with PGE2 by ELISA and Western blotting assays, respectively. PGE2 dose-dependently increased intracellular cAMP contents (Supplementary Figure S2C) , and robustly activated PKA (Figure 5a ). Moreover, pretreatment of cells with PKA inhibitor, H-89, not only dose-dependently inhibited the accumulation of SVCT2 in plasma membrane but also concurrently increased SVCT2 in cytoplasm in response to PGE2 (Figure 4c ), which is consistent with the results from uptake assay and immunostaining indicating that H-89 dosedependently attenuated PGE2-induced AA uptake ( Figure 4f ) and H-89 at 10 mM almost completely ablated PGE2-induced SVCT2 plasma membrane accumulation (Figure 4k ). Moreover, H-89 significantly inhibited PGE2-induced ALP activity as well as Hyp contents in a dose-dependent manner (Supplementary Figure S2D) . Overall, these data indicate that PGE2 stimulates SVCT2 plasma membrane localization and AA uptake through a signaling cascade involving EP4-AC-cAMP-PKA.
PKA phosphorylates SVCT2 at Ser402 and Ser639 sites. To examine the likely physical interaction between PKA and SVCT2, we performed co-immunoprecipitation using whole cell lysates with anti-catalytic PKA unit (cPKA) or anti-SVCT2 antibodies. Protein complexes in the immunoprecipitates were detected by Western blotting with the indicated antibodies (Figure 5a ). The protein complexes from either vehicle-or PGE2-treated cells precipitated with a SVCT2 antibody containing cPKA in addition to SVCT2 as expected, and the complexes from PGE2-treated but not vehicle-treated cells precipitated with a cPKA antibody containing SVCT2 in addition to cPKA as expected; however, precipitates from the control IgG, on the other hand, did not contain any proteins (Figure 5a) .
To determine the functional consequences of physical interaction between cPKA and SVCT2, we analyzed the primary structure of mSVCT2, finding that two putative PKA phosphorylation sites (Ser402 and Ser639) located in Cterminal (Figure 5b ). To assess their potential importance, we expressed myc-tagged wild type of SVCT2 (WT) and SVCT2 variants that harbored mutations at the serine residues (Ser to Ala) individually (S402A, S639A) or in combination (S402/ 639A), and performed in vitro phosphorylation assays by using purified active PKA catalytic unit, followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography. The wild-type SVCT2 incorporated robust levels of 32 P, whereas both S402A and S639A showed marked reduction, as expected, the double mutant, S402/639A incorporated no 32 P (Figure 5c ). Western blotting using the myc antibody further confirmed that the 32 P-labeled bands corresponded to the SVCT2 variants, and similar levels of myc-tagged SVCT2 variants were present among the various immunoprecipitates (Figure 5c ). To confirm that S402 and S639 are phosphorylated in intact cells responding to PGE2, we performed in vivo phosphorylation assays. Under basal conditions, no significant phosphorylation was detected for any of the SVCT2 variants. However, upon PGE2 stimulation, the wild-type SVCT2 became highly phosphorylated (Figure 5d ), both S402A and S639A largely reduced phosphorylation and S402/639A completely abolished phosphorylation in response to PGE2 (Figure 5d ). Western blotting using the myc antibody revealed similar levels of myc-SVCT2 variants among the immunoprecipitates, indicating that the different variants were expressed at similar levels (Figure 5d ). Together, these data convincingly demonstrate that SVCT2 can be phosphorylated by PKA at Ser402 and Ser639 sites both in vitro and in intact cells.
Ser402 and Ser639 are critical for SVCT2 plasma membrane localization. To understand the contribution of SVCT2 phosphorylation by PKA, we performed transient transfection with myc-tagged SVCT2 variants and immunostaining to examine the subcellular localization of myc-tagged SVCT2 variants by using a myc antibody. MC3T3-E1 cells were transfected with pCS2-MT-SVCT2, pCS2-MT-SVCT2 S402A pCS2-MT-SVCT2 S639A or pCS2-MT-SVCT2 S402/639A expression vector, after transfection, cells were stimulated with 1 mM of PGE2 for 1 h, and the subcellular localization of myc-tagged proteins were detected by mouse anti-myc first antibody and anti-mouse Alex555 second antibody under confocal microscopy. Without PGE2 stimulation, myc-tagged wide-type SVCT2 was distributed diffusely in the cytoplasm ( Figure 6a) ; however, under stimulation of PGE2, myc-tagged wide-type SVCT2 was mainly detected in the portion of plasma membrane (Figure 6b ). In contrast, even though stimulation of PGE2, the myc-tagged SVCT2 PGE2 is among the most important local factors with autocrine/paracrine roles in the bone. 28 PGE2 treatment for different times stimulates not only early-stage differential markers including ALP and collagen expression but also latestage marker, OCN expression, and mineralization, which correspond to previous reports indicating that PGE2 induces ALP activity and collagen synthesis 21, 22 as well as OCN expression 29 and mineralization. 23, 24 The same effects of PGE2 were observed in primary calvarial culture system, suggesting that PGE2 plays an important role in bone formation. Although Kajii et al. reported that indomethacin induces ALP activity, collagen synthesis, and mineralization in MC3T3-E1 cells, in our system, we added 1 mg/ml of indomethacin to inhibit completely endogenous PGE2 production from MC3T3-E1 cells both in vehicle-and PGE2-containing medium; 30 therefore, the abovementioned effects Figure 5 Physical interactions between PKA and SVCT2 and phosphorylation assays in vitro, and in intact cells. For co-immunoprecipitation, MC3T3-E1 cells were precultured in serum-free aMEM containing 1 mg/ml of indomethacin for 3 h, and further treated along with or without PGE2 for 1 h. After treatment, whole cell lysis was harvested, and the proteins were immunoprecipitated with normal serum IgG, SVCT2 (a-SV) or cPKA (a-PK) antibodies followed by SDS-PAGE and Western blotting for detection of cPKA and SVCT2 antigen (a). Putative phosphorylation sites for PKA in SVCT2 were shown (b). For in vitro phosphorylation assay, cells were transiently transfected with myc-tagged SVCT2 or its variants, and the myc-tagged proteins were purified by anti-myc-agarose beads, and subjected to a kinase reaction with [g-32 P]ATP catalyzed with ( þ ) or without (À) the purified catalytic subunit of PKA (cPKA). Whole kinase reactions (c) were subjected to electrophoresis, followed by autoradiography (upper bands) and Western blotting with myc-antibody (lower bands). For phosphorylation assay of SVCT2 in intact cells, MC3T3-E1 cells were transfected with empty vector, myc-tagged SVCT2 or the corresponding variants, 2 days after transfection, cells were cultured in a phosphate-free medium containing 0.25 mci/ml of [ 32 P]orthophosphate, followed by stimulation with 1 mM PGE2 for 1 h. The proteins were immunoprecipitated with myc antibody followed by electrophoresis, autoradiography (upper bands), and Western blotting with myc antibody (lower bands) (d). Experiments were independently duplicated, and results were qualitatively identical. Representative experiments are shown Phosphorylation of SVCT2 on osteogenesis X Wu et al of PGE2 are derived from exogenous PGE2 rather than indomethacin and endogenous PGE2. It is well documented that indomethacin inhibits PGE2 production through nonselective inhibition of cyclo-oxygenase (COX) in MC3T3-E1 cells, 31 our results indicate that PGE2 obviously induces osteoblast-like differentiation, suggesting that induction of osteoblast-like differentiation by indomethacin may have resulted from inhibition of COX-2 rather than from inhibition of PGE2 production, and this notion was further supported by previous report. 32 We previously found that overexpression of SVCT2 and consequent increase of AA uptake into MC3T3-E1 cells lead to induction of osteoblast-like differentiation, 12 implying that any factor able to increase AA uptake into MC3T3-E1 cells might result in stimulation of osteoblast-like differentiation. In this study, we reveal that PGE2 stimulates AA uptake with increases in V max and no change in K m , indicating that PGE2 stimulates AA incorporation by increasing SVCT2 activity rather than increasing the affinity to SVCT2, which corresponds to our another finding that PGE2 induces AA uptake through increase of SVCT2 localization in plasma membrane instead of induction of SVCT2 mRNA or protein expression in MC3T3-E1 cells. Additionally, we first cloned mouse dnSVCT2 cDNA and indicate that overexpression of dnSVCT2 functionally leads to decreases of V max but not K m value in AA uptake and no effect on endogenous SVCT2 levels, consistent with previous report that human dnSVCT2 gives rise to a nonfunctional transport and acts as a dominantnegative mutant in AA uptake. 25 Overexpression of dnSVCT2 decreases the basal levels of ALP, collagen, OCN expression, and mineralization, corresponding to our previous findings that overexpression of SVCT2 stimulates osteoblast-like differentiation, 12 and Ca 2 þ , PO 4
3À
, or Zn 2 þ enhances osteoblast-like differentiation through increase of SVCT2 expression and AA uptake into MC3T3-E1 cells. 10, 11 In addition to decreasing the basal levels of osteoblast differential markers expression and mineralization, dnSVCT2 also marvelously attenuates PGE2-induced differential markers including ALP, collagen, and OCN expression as well as mineralization, providing the evidence that SVCT2 and AA uptake mediate PGE2-induced osteoblast-like differentiation.
Moreover, PGE2 neither induces SVCT2 mRNA expression nor increases SVCT2 protein levels in whole cells, implying that PGE2-induced AA uptake is not resulted from upregulation of SVCT2 expression in MC3T3-E1 cells. Furthermore, Western blotting results indicate that PGE2 time-and dose-dependently increases SVCT2 levels in plasma membrane, and concurrently decreases SVCT2 levels in cytoplasm, which is consistent with the immunostaining results indicating that PGE2 drives SVCT2 to plasma membrane from cytoplasm without obvious change of SVCT2 protein levels in whole MC3T3-E1 cells. Among various transporters, it is common that they exert their functions through subcellular redistribution. Insulin stimulates glucose uptake in adipocytes, skeletal, and cardiac muscles by promoting the subcellular redistribution of GLUT4, one of oxidative vitamin C transporter also serving as a facilitative glucose transporter, from an intracellular compartment (GLUT4 storage vesicle) to the plasma membrane. [33] [34] [35] For hSVCT1, decrease in AA uptake in COS-1 cells treated with PKC inhibitor is associated with a redistribution of hSVCT1 from the cell surface to intracellular membranes.
36
EP1 receptor inhibitor, AH-6809, does not affect PGE2-induced SVCT2 translocation, AA uptake, osteoblast differential markers expression, and mineralization, suggesting that PGE2-associated effects are not due to activation of EP1 receptor subtype. However, EP4 receptor inhibitor, AH-23848B abrogates PGE2-associated effects, suggesting that activation of EP4 subtype and subsequent increase of cAMP contents are involved in PGE2-associated effects. PGE2-induced elevation of cAMP through EP4 receptor results in an increase in PKA activity in various cell types, 37 thus, cAMPdependent PKA activation might play a key role in PGE2-associated effects in MC3T3-E1 cells. This notion is further supported by our findings that H-89, a PKA inhibitor, reduces PGE2-induced ALP activity, Hyp contents, AA uptake, and SVCT2 membrane translocation.
Putative membrane topology analysis of rat SVCT1 and SVCT2 predicated five potential sites for protein kinase Cdependent phosphorylation. Additional cAMP-dependent phosphorylation sites are present in the C-terminal of SVCT1 and SVCT2. 5, 38 Activation of PKC has been shown to inhibit S402A (S402A), pCS2-MT-SVCT2 S639A (S639A) or double mutant pCS2-MT-SVCT2 S402/639A (S402/639A) expression vector by lipofectamine. Then, cells were precultured in serum-free aMEM containing 1 mg/ml of indomethacin for 3 h, and then treated along with 1 mM PGE2 for additional 1 h. Immunostaining was performed by using mouse anti-myc first antibody and anti-mouse Alex555-conjugated second antibody. Stained cells were examined under an Olympus confocal microscope (bars, 100 mm) Na þ -dependent vitamin C transport in a cell line derived from rabbit nonpigmented ciliary epithelium and in oocytes expressing hSVCT1 and hSVCT2. 6, 39 PKC activator phorbol 12-myristate 13-acetate (PMA) causes a time-and concentration-dependent decrease in AA transport activity in COS-1 cells, for hSVCT1 but not hSVCT2, 36 the decrease in AA uptake is correlated with a redistribution of the transporter from the cell surface to intracellular membranes. In our case, the immunocomplexes precipitated by SVCT2 antibody contain cPKA under stimulation with PGE2 or without PGE2 indicating that the specifically physical interaction between SVCT2 and cPKA is PGE2-independent, however, the immunocomplexes precipitated by cPKA antibody contain SVCT2 only after exposure to PGE2 suggesting PGE2-dependent interaction between SVCT2 and cPKA. This discrepancy might be due to the antibody issue or other molecules existing in the complexes. Thus, PGE2 signaling does not appear to control PKA and SVCT2 complex formation, but may instead phosphorylate SVCT2 by PKA within the complex.
Recent report demonstrated that PGE2, through PKA activation, promotes b-catenin signaling in colon cancer cells, and the promoting effect of PKA is attributed to phosphorylation and inactivation of GSK3. 40 In mouse SVCT2, two putative PKA phosphorylation consensus sites residing in the fifth intracellular loop between transmembrane domain 10 and transmembrane domain 11 (Ser402) and in C-terminal (Ser639), respectively, this two putative sites were hydrophilic as predicated by topology assay. Our present finding reveals that in PKA-SVCT2 complex, SVCT2 serves as a substrate of PKA, and PKA activation by PGE2 phosphorylates SVCT2 at both Ser402 and Ser639 sites of SVCT2 protein, this finding was not reported previously. As S402A, S639A, and double mutation surely attenuate the phosphorylation of SVCT2, we propose one potential mechanism wherein phosphorylation of SVCT2 by PKA at Ser402 and Ser639 sites promotes the plasma membrane translocation of SVCT2, thereby, our data indicated that S402A and S639A mutations nearly abolish SVCT2 plasma membrane translocation under stimulation of PGE2, supporting this notion that phosphorylation of SVCT2 at Ser402 and Ser639 sites is required for PGE2-induced SVCT2 plasma membrane translocation. However, why the phosphorylated SVCT2 is subjected to plasma membrane translocation is not understood and is worth further study in future.
In summary, by using biochemical and molecular biological approaches the present study has uncovered a signaling cascade that operates in conjunction with PGE2-induced SVCT2 plasma membrane localization to osteoblast-like differentiation (Figure 7) . In this cascade, PGE2 signals activate PKA through EP4 receptor and most likely AC and cAMP. As a result, cytoplasm SVCT2 is phosphorylated by PKA at Ser402 and Ser639 sites and thereby localized to the plasma membrane to facilitate AA uptake into cells, which further leads to promotion of osteoblast-like differentiation in MC3T3-E1 cells.
Materials and Methods
Plasmid constructions. The full-length of murine SVCT2 cDNA was amplified by PCR as described previously, 9 and cloned into 6 Â myc-epitopetagged expression vector, pCS2-MT at XbaI site, named pCS2-MT-SVCT2. Point mutants at the putative PKA phosphorylation sites of SVCT2, named pCS2-MT-SVCT2
S402A
, pCS2-MT-SVCT2
S639A
, and pCS2-MT-SVCT2 S402/609A were generated by using pCS2-MT-SVCT2 and appropriate oligonucleotides with the Stratagene QuickChange site-directed mutagenesis method (Stratagene, Cedar Creek, TX, USA). All these plasmids were confirmed by sequencing. For cloning SVCT2 short isoform (dnSVCT2), cDNA from MC3T3-E1 cells (ATCC, Rockville, MD, USA) was used as a template for PCR-cloning of mouse dnSVCT2, and oligonucleotide primers were arranged as follows: 5 0 -GTCTTGATGA TGGGTATCGG-3 0 (sense) and 5 0 -CTATACTGTGGCCTGGGAAT-3 0 (antisense). The PCR products contained B2 kb (SVCT2 full-length cDNA) and B1.6 kb (dnSVCT2) length fragments, and the short fragment was cloned into the retroviral expression vector, pLXRN (Clontech Laboratories Inc., Mountain View, CA, USA) at SalI and AvrII sites, the construct named pLXRN-dnSVCT2 was verified by a DNA sequencer. Moreover, EGFP cDNA was subcloned into pLXRN to form the construct named pLXRN-EGFP as a control expression vector.
Cell culture and treatment. MC3T3-E1 cells were maintained in amodification of Eagle's medium (aMEM, ICN Biomedicals Co, Aurora, OH, USA) containing 50 mg/l of AA and 10% fetal calf serum in 5% CO 2 at 371C. For PGE2 (Cayman Chemicals, Ann Arbor, MI, USA) treatment, cells were previously exposed in serum-free aMEN medium containing 1 mg/ml of indomethacin (Nakalai Tesque, Kyoto, Japan) for 3 h and further treated along with the indicated concentrations of PGE2, indomethacin was used for inhibition of endogenous PGE2 production. ALP activity, Hyp content measurement and von Kossa staining. Determination of ALP activity was performed as described previously, 12 and the activity was expressed as nanomoles of p-nitrophenol formed per minute per milligram of protein. Hyp contents were evaluated by Woessner's method 13 and were expressed as mg/10 5 cells. von Kossa's staining was processed to monitor the mineralized nodules by using 5% silver nitrate, as described previously. and hybridized with the blots. Messenger RNA signals were detected and analyzed by using the BAS 1500 Mac radioimaging system (Fuji Film, Tokyo, Japan). All membranes were reprobed with a 32 P-labeled DNA probe for mouse 18S rRNA as an internal control.
[l- 14 C]AA uptake. The uptake assay was described previously. 10, 11 Briefly, after a rinse with incubation buffer (in mM: 140 NaCl, 4.2 KHCO 3 , 5.8 KCl, 1.3 CaCl 2 , 0.5 MgCl 2 , 10 HEPES, and 1 dithiothreitol, pH 7.4), cells were incubated with 6.25, 12.5, 25, 50 or 100 mM (for kinetic parameter assays) or 25 mM (for single dose uptake assays) [l-
14 C]AA (Perkin-Elmer Life Science) at 371C for 30 min, and the incorporated radioactivity was measured with a liquid scintillation counter. Kinetic constants of transport, the apparent Michaelis-Menten constant (K m ) and the maximal rate of AA uptake (V max ) were calculated from specifically incorporated radioactivity with various concentrations of AA by fitting data to a double reciprocal plot. Specific uptake was calculated as the total incorporated radioactivity in the absence of cold AA minus the nonspecific radioactivity in excessive cold AA (10 mM). AA uptake appeared to increase linearly within 1 h under these experimental conditions. Retroviral gene expression system. GP293 retroviral packaging cells (Clontech) were maintained in Dulbecco's modified Eagle medium containing 10% FCS. Cells were transiently cotransfected with 4 mg of pVSV-G vector (Clontech) plus 5 mg of either pLXRN-dnSVCT2 or pLXRN-EGFP by the lipofectamin (Invitrogen). After transfection, medium was changed to regular medium, and retrovirus-containing supernatants were harvested 48 h after transfection, virus was concentrated by ultracentrifugation according to the manufacturer's protocol, and the retroviral supernatants with titer more than 1 Â 10 6 cfu/ml were used for infection. MC3T3-E1 cells were exposed to retrovirus containing medium for 24 h in the presence of 6 mg/ml of polybrene (Nacalai Tesque), and the infection efficiency was determined by EGFP-positive cells (more than 90%). After infection, viruscontaining medium was changed to desired experimental condition for assessment of dnSVCT2 and SVCT2 protein expression, AA uptake, ALP activity, Hyp contents, OCN expression, and mineralization in either dnSVCT2 or EGFP expressing virusinfected MC3T3-E1 cells with or without PGE2 stimulation. Subcellular fractions and Western blotting. For preparation of whole cell lysis, cells were washed twice with ice-cold phosphate-buffered saline (PBS), harvested and transferred to lysis buffer containing 25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM MgCl 2 , 1% NP-40, 1 mM DTT, and 5% glycerol and further incubated at 41C for 20 min, then, mixture was centrifuged at 12 000 Â g for 30 min, and supernatant was used as whole cell lysis for Western blotting. For preparation of subcellular fractions, cells were rinsed twice with PBS and harvested, then, cells were homogenized in 0.6 ml of ice-cold homogenization buffer A (10 mM HEPES-KOH, pH 7.2, 0.25 M sucrose) containing a complete protease inhibitor mixture (Roche Diagnostics) by a glass Dounce homogenizer, and centrifuged at 2500 r.p.m. for 10 min at 41C to remove nuclei and unbroken cells. The postnuclear supernatant was then centrifuged at 120 000 Â g for 60 min at 41C to obtain cytosol and membrane fractions. The supernatant was used as a cytosol fraction, and the pellet was further rinsed with homogenization buffer A twice, dissolved in lysis buffer (50 mM Tris-HCl, pH 7.5, 1% Triton X-100, 2.5 mM EDTA, 0.25 M NaCl), and centrifuged at 12 000 r.p.m. for 10 min at 41C, the supernatant was used as a membrane fraction. Western blotting was described previously, 11, 12 briefly, protein samples were separated by 10% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). Antigens on the membrane were first probed with desired first antibody including rabbit anti-SVCT2 antibody 11 and mouse anti-OCN antibody (SC-1822, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and then horse peroxidase-conjugated anti-rabbit or anti-mouse secondary antibody (Santa Cruz Biotechnology). The immunoreactive bands were visualized by enhanced ECL system (Amersham-Pharmacia).
Immunostaining of endogenous SVCT2 and myc-tagged SVCT2. To determine the effect of PGE2 and inhibitors on subcellular localization of endogenous SVCT2, cells seeded at 0.75 Â 10 4 /cm 2 were cultured overnight in regular medium, and directly switched to the serum-free medium for 24 h, then, cells were pretreated with inhibitors for 3 h, and further treated along with PGE2 (1 mM) for 1 h. To examine the effect of PGE2 on subcellular localization of myc-tagged SVCT2, cells were transfected with proper amount of pCS2- MT-SVCT2, pCS2-MT-SVCT2   S402A   , pCS2-MT-SVCT2  S639A or pCS2-MT-SVCT2   S402/639A expression vector, after transfection, cells were cultured in regular medium for 24 h, starved for additional 24 h, and further treated with 1 mM PGE2 for 1 h. For immunostaining, cells were fixed in PBS-buffered 3.7% formaldehyde containing 30 mM sucrose for 10 min, neutralized in 50 mM NH 4 Cl for 10 min, before permeabilized with 0.1% Triton X-100/PBS for 30 min. After blocking in 1% BSA plus 1% normal sheep serum, the cells were then incubated with anti-rabbit SVCT2 or anti-mouse myc primary antibody (Santa Cruz) for 60 min, washed in 0.1% Triton X-100/PBS, and finally incubated with anti-rabbit or anti-mouse Alexa555-conjugated secondary antibody (Invitrogen). As controls for specificity, some cells were stained with the secondary antibody only. All procedures were performed at room temperature. Stained cells were examined under an Olympus confocal microscope.
Immunoprecipitation. The lysates from PGE2-treated or transfected MC3T3-E1 cells were used for immunoprecipitation. The cells were washed twice with ice-cold PBS and lysed in the extraction buffer (300 ml/10 6 cells) containing 150 mM NaCl, 25 mM HEPES (pH 7.4), 0.5% Nonidet P-40, 2 mM EDTA, 2 mM EGTA, 100 mM orthovanadate, and protease inhibitor cocktail. The lysates were cleared by centrifugation at 15 000 Â g for 10 min, and the immunoprecipitation of endogenous PKA and SVCT2 was performed by using rabbit anti-cPKA (Santa Cruz) and rabbit anti-SVCT2 antibodies, respectively. While the immunoprecipitation for MC3T3-E1 cells transfected with pCS2-MT-SVCT2, pCS2-MT-SVCT2 S402A , pCS2-MT-SVCT2 S639A or pCS2-MT-SVCT2 S402/639A expression vector was performed by using mouse anti-myc antibody. At the same time, immunoprecipitates with normal nonimmune IgG serum instead of specific antibody were used as an internal negative control. Immunoprecipitations were performed by overnight incubation of the cleared protein A-conjugated agarose beads followed by four times washes with 1 ml of lysis buffer. The PKA and SVCT2 immune complex was boiled in 2 Â sample buffer and subjected to Western blotting with the desired antibody. Myc-tagged SVCT2 and its mutants immune complex was subjected to phosphorylation assay in vitro and in intact cells.
In Vitro

32
P labeling of SVCT2. MC3T3-E1 cells were transfected with proper amount of pCS2-MT-SVCT2, pCS2-MT-SVCT2 S402A pCS2-MT-SVCT2 S639A or pCS2-MT-SVCT2 S402/639A expression vector, after transfection, cells were cultured in regular medium for 24 h, then, cells were starved for an additional 24 h, and further stimulated with 1 mM PGE2 for 1 h. The myc-tagged protein were purified by anti-myc-agarose beads, the beads were washed once with PKA assay buffer (20 mM Tris-HCl (pH 7.4), 100 mM NaCl, 10 mM MgCl 2 , 1 mM ATP), and then incubated with 45 ml of PKA assay buffer supplemented with 0.1 mM dithiothreitol, five units of purified protein kinase A catalytic subunit (Promega, Madison, WI, USA), and 5 mCi of [g- 32 P]ATP (Perkin-Elmer) at 301C for 30 min. The reaction was stopped by the addition of 15 ml of 4 Â sample buffer and boiling for 5 min. Proteins were subjected to SDS-PAGE, followed by autoradiography and Western blotting with anti-myc antibody. S639A or pCS2-MT-SVCT2 S402/639A expression vector, after transfection, cells was cultured in regular medium for 24 h, and starved for additional 24 h. Then, cells were incubated with 0.25 mCi/ml [ 32 P]orthophosphate (Perkin-Elmer) in both phosphate-and serum-free medium for 3 h, followed by three washes and stimulation with 1 mM of PGE2 for 1 h. Cells were then lysated, and the lysis was subjected to immunoprecipitation with myc antibody as described above, followed by electrophoresis, autoradiography, and Western blotting with myc antibody.
Statistical analysis. Numerical data were expressed as means7S.D. and analyzed by ANOVA and Tukey-Kramer multiple comparisons test. Statistical significance was assessed at levels of Po0.05 and Po0.01. Experiments were independently triplicated and results were qualitatively identical. Representative experiments are shown.
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